Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NW38

UPID:
FANCL_HUMAN

ALTERNATIVE NAMES:
Fanconi anemia group L protein; Fanconi anemia-associated polypeptide of 43 kDa; RING-type E3 ubiquitin transferase FANCL

ALTERNATIVE UPACC:
Q9NW38; Q6GU60

BACKGROUND:
The RING-type E3 ubiquitin transferase FANCL is integral to the cellular mechanism for repairing damaged DNA. By facilitating the monoubiquitination of FANCD2 and FANCI, FANCL ensures the integrity of the genome and supports cell survival following DNA damage. Its role extends to germ cell proliferation, highlighting its importance in both embryonic development and adult tissue maintenance.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in the DNA damage response pathway, FANCL's malfunction is associated with Fanconi anemia, characterized by genomic instability and predisposition to cancer. Understanding the role of E3 ubiquitin-protein ligase FANCL could open doors to potential therapeutic strategies, offering hope for patients with Fanconi anemia and possibly contributing to the development of novel cancer treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.